Protective role of sulforaphane in lipid metabolism-related diseases
- PMID: 39961997
- DOI: 10.1007/s11033-025-10358-w
Protective role of sulforaphane in lipid metabolism-related diseases
Abstract
Sulforaphane (SFN) is a phytochemical bioactive substance commonly found in cruciferous plants, such as broccoli and mustard. It has been reported to possess antibacterial, anti-inflammatory, anti-oxidant, anti-cancer and autophagy regulating properties. Recent studies have revealed that SFN regulates fat metabolism both in vivo and in vitro through various mechanisms, including alleviating endoplasmic reticulum stress, inhibiting inflammatory response and improving mitochondrial dysfunction, involving Nrf2/ARE, NF-κB, NLRP3 inflammasome, HDAC8-PGC1α axis and other signaling pathways. By curbing complications associated with abnormal fat metabolic diseases, SFN exhibits therapeutic effects on conditions like obesity, fatty liver disease, atherosclerosis, type 2 diabetes, etc., with minimal side effects. Therefore, it holds promise as a potential alternative treatment for lipid metabolism-related diseases. Although its extraction method has been matured, the thermal instability and preservation difficulties of SFN limit its clinical promotion. More effective and low-cost methods to improve the stability and production of SFN remain to be further studied. This paper reviews the physiological and biological activities of SFN, and summarizes the protective effects and molecular mechanisms of SFN in diseases related to abnormal lipid metabolism. Additionally, it proposes potential challenges, possible solutions and future research directions in the clinical application of SFN.
Keywords: Atherosclerosis; Fatty liver; Obesity; Sulforaphane; Type 2 diabetes mellitus.
© 2025. The Author(s), under exclusive licence to Springer Nature B.V.
Conflict of interest statement
Declarations. Conflicts of interest: The authors declare no conflict of interest. Informed consent: Not applicable.
References
-
- Pafili K, Roden M (2021) Nonalcoholic fatty liver disease (NAFLD) from pathogenesis to treatment concepts in humans. Mol Metab 50:101122 - PubMed
-
- DeMarsilis A et al (2022) Pharmacotherapy of type 2 diabetes: an update and future directions. Metabolism 137:155332 - PubMed
-
- Panjwani AA, Liu H, Fahey JW (2018) Crucifers and related vegetables and supplements for neurologic disorders: what is the evidence? Curr Opin Clin Nutr Metab Care 21:451–457 - PubMed
-
- Zhang Z et al (2024) Sulforaphane reduces adipose tissue fibrosis via promoting M2 macrophages polarization in HFD fed-mice. Biochim Biophys Acta Mol Cell Res 1871:119626 - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous
